- Home
- BMRA vs KPRX Comparison
BMRA vs KPRX Comparison
Compare BMRA & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRA
- KPRX
- Stock Information
- Founded
- BMRA 1971
- KPRX 1998
- Country
- BMRA United States
- KPRX United States
- Employees
- BMRA N/A
- KPRX N/A
- Industry
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BMRA Health Care
- KPRX Health Care
- Exchange
- BMRA Nasdaq
- KPRX Nasdaq
- Market Cap
- BMRA 8.2M
- KPRX 9.2M
- IPO Year
- BMRA N/A
- KPRX N/A
- Fundamental
- Price
- BMRA $2.96
- KPRX $2.54
- Analyst Decision
- BMRA
- KPRX Strong Buy
- Analyst Count
- BMRA 0
- KPRX 1
- Target Price
- BMRA N/A
- KPRX $10.00
- AVG Volume (30 Days)
- BMRA 250.1K
- KPRX 55.1K
- Earning Date
- BMRA 10-14-2025
- KPRX 11-07-2025
- Dividend Yield
- BMRA N/A
- KPRX N/A
- EPS Growth
- BMRA N/A
- KPRX N/A
- EPS
- BMRA N/A
- KPRX N/A
- Revenue
- BMRA $4,884,000.00
- KPRX N/A
- Revenue This Year
- BMRA N/A
- KPRX N/A
- Revenue Next Year
- BMRA N/A
- KPRX N/A
- P/E Ratio
- BMRA N/A
- KPRX N/A
- Revenue Growth
- BMRA N/A
- KPRX N/A
- 52 Week Low
- BMRA $2.08
- KPRX $2.21
- 52 Week High
- BMRA $10.16
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- BMRA 50.63
- KPRX 47.82
- Support Level
- BMRA $2.82
- KPRX $2.21
- Resistance Level
- BMRA $3.19
- KPRX $2.68
- Average True Range (ATR)
- BMRA 0.20
- KPRX 0.15
- MACD
- BMRA 0.02
- KPRX -0.01
- Stochastic Oscillator
- BMRA 56.53
- KPRX 54.05
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.